Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient.

Breville G, Lascano AM, Merkler D, Roth S, Lalive PH.

Mult Scler Relat Disord. 2019 Sep;34:63-65. doi: 10.1016/j.msard.2019.06.017. Epub 2019 Jun 17.

PMID:
31229736
2.

Encephalitis and meningoencephalitis: chasing the culprit.

Schibler M, Zanella MC, Kaiser L, Lalive PH.

Clin Microbiol Infect. 2019 Apr;25(4):406-407. doi: 10.1016/j.cmi.2019.01.013. Epub 2019 Jan 29. No abstract available.

PMID:
30703529
3.

Pachymeningitis with optic neuropathy associated with extrapulmonary tuberculosis and secondary antiphospholipid syndrome.

De Stefano P, Lascano AM, Schibler M, Fitsiori A, Janssens JP, Lalive PH, Gschwind M.

Mult Scler Relat Disord. 2019 Apr;29:83-85. doi: 10.1016/j.msard.2019.01.026. Epub 2019 Jan 15. No abstract available.

PMID:
30685445
4.

Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.

Lalive PH, Roth S, Du Pasquier R.

Neurology. 2019 Jan 15;92(3):151. doi: 10.1212/WNL.0000000000006773. No abstract available.

PMID:
30643033
5.

A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosis.

Baert L, Benkhoucha M, Popa N, Ahmed MC, Manfroi B, Boutonnat J, Sturm N, Raguenez G, Tessier M, Casez O, Marignier R, Ahmadi M, Broisat A, Ghezzi C, Rivat C, Sonrier C, Hahne M, Baeten D, Vives RR, Lortat-Jacob H, Marche PN, Schneider P, Lassmann HP, Boucraut J, Lalive PH, Huard B.

Ann Neurol. 2019 Mar;85(3):406-420. doi: 10.1002/ana.25415. Epub 2019 Feb 4.

PMID:
30635946
6.

Diagnostic tools for immune causes of encephalitis.

Lascano AM, Vargas MI, Lalive PH.

Clin Microbiol Infect. 2019 Apr;25(4):431-436. doi: 10.1016/j.cmi.2018.12.012. Epub 2018 Dec 22. Review.

PMID:
30583056
7.

AQP4 antibody-positive NMO spectrum disorder associated with Takayasu arteritis.

Lamartine S Monteiro M, Lascano AM, Meunier Carus Vincent N, Seebach JD, Lalive PH, Gschwind M.

J Neurol Sci. 2019 Jan 15;396:130-132. doi: 10.1016/j.jns.2018.11.016. Epub 2018 Nov 13. No abstract available.

PMID:
30453208
8.

Investigation of the global protein content from healthy human tears.

Dor M, Eperon S, Lalive PH, Guex-Crosier Y, Hamedani M, Salvisberg C, Turck N.

Exp Eye Res. 2019 Feb;179:64-74. doi: 10.1016/j.exer.2018.10.006. Epub 2018 Oct 13.

PMID:
30321513
9.

Limbic encephalitis associated with systemic sclerosis.

De Stefano P, Chizzolini C, Lalive PH, Lascano AM.

Mult Scler Relat Disord. 2018 Aug;24:142-144. doi: 10.1016/j.msard.2018.06.019. Epub 2018 Jul 10.

PMID:
30005357
10.

[Immunization and autoimmune neurological diseases].

Lalive PH.

Rev Med Suisse. 2018 May 2;14(605):934-937. French.

PMID:
29722499
11.

Syndrome de Guillain-Barré.

Nemitz I, Lascano AM, Lalive PH, Plan PA.

Rev Med Suisse. 2018 Apr 11;14(602):807-809. French. No abstract available.

PMID:
29658222
12.

Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.

Zecca C, Roth S, Findling O, Perriard G, Bachmann V, Pless ML, Baumann A, Kamm CP, Lalive PH, Czaplinski A.

Eur J Neurol. 2018 May;25(5):762-767. doi: 10.1111/ene.13594. Epub 2018 Mar 6.

13.

Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.

Lingenberg A, Laidet M, Armand S, Herrmann FR, Assal F, Lalive PH, Allali G.

J Neurol Sci. 2017 Dec 15;383:105-107. doi: 10.1016/j.jns.2017.10.049. Epub 2017 Oct 31. No abstract available.

PMID:
29246593
14.

Does fear of falling predict gait variability in multiple sclerosis?

Laidet M, Herrmann FR, Armand S, Assal F, Lalive PH, Allali G.

J Neurol Sci. 2017 Sep 15;380:212-214. doi: 10.1016/j.jns.2017.07.034. Epub 2017 Jul 25.

PMID:
28870571
15.

Identification of a novel population of highly cytotoxic c-Met-expressing CD8+ T lymphocytes.

Benkhoucha M, Molnarfi N, Kaya G, Belnoue E, Bjarnadóttir K, Dietrich PY, Walker PR, Martinvalet D, Derouazi M, Lalive PH.

EMBO Rep. 2017 Sep;18(9):1545-1558. doi: 10.15252/embr.201744075. Epub 2017 Jul 27.

16.

Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.

Lalive PH, Kreutzfeldt M, Devergne O, Metz I, Bruck W, Merkler D, Pot C.

J Neuroinflammation. 2017 Jul 24;14(1):144. doi: 10.1186/s12974-017-0919-1.

17.

Clinical evoked potentials in neurology: a review of techniques and indications.

Lascano AM, Lalive PH, Hardmeier M, Fuhr P, Seeck M.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):688-696. doi: 10.1136/jnnp-2016-314791. Epub 2017 Feb 24. Review.

PMID:
28235778
18.

Activation of human B cells negatively regulates TGF-β1 production.

Molnarfi N, Bjarnadóttir K, Benkhoucha M, Juillard C, Lalive PH.

J Neuroinflammation. 2017 Jan 19;14(1):13. doi: 10.1186/s12974-017-0798-5.

19.

Postural control is associated with cognition and fear of falling in patients with multiple sclerosis.

Perrochon A, Holtzer R, Laidet M, Armand S, Assal F, Lalive PH, Allali G.

J Neural Transm (Vienna). 2017 Apr;124(4):495-500. doi: 10.1007/s00702-016-1668-5. Epub 2016 Dec 22.

PMID:
28005172
20.

Gait Profile Score in multiple sclerosis patients with low disability.

Morel E, Allali G, Laidet M, Assal F, Lalive PH, Armand S.

Gait Posture. 2017 Jan;51:169-173. doi: 10.1016/j.gaitpost.2016.10.013. Epub 2016 Oct 18.

PMID:
27776271
21.

B cell-derived transforming growth factor-β1 expression limits the induction phase of autoimmune neuroinflammation.

Bjarnadóttir K, Benkhoucha M, Merkler D, Weber MS, Payne NL, Bernard CCA, Molnarfi N, Lalive PH.

Sci Rep. 2016 Oct 6;6:34594. doi: 10.1038/srep34594.

22.

Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes.

Carbone F, Satta N, Montecucco F, Virzi J, Burger F, Roth A, Roversi G, Tamborino C, Casetta I, Seraceni S, Trentini A, Padroni M, Dallegri F, Lalive PH, Mach F, Fainardi E, Vuilleumier N.

Eur J Clin Invest. 2016 Sep;46(9):805-17. doi: 10.1111/eci.12664.

PMID:
27490973
23.

[Paraneoplastic neurological syndromes: an update].

Zekeridou A, Ferfoglia RI, Du Pasquier R, Lalive PH.

Rev Med Suisse. 2016 Apr 27;12(516):832-4, 836-9. French.

PMID:
27281941
24.

Stride time variability as a marker for higher level of gait control in multiple sclerosis: its association with fear of falling.

Allali G, Laidet M, Armand S, Elsworth-Edelsten C, Assal F, Lalive PH.

J Neural Transm (Vienna). 2016 Jun;123(6):595-9. doi: 10.1007/s00702-016-1551-4. Epub 2016 Apr 22.

PMID:
27106906
25.

[Primary progressive multiple sclerosis: a treatment turns out to be finally effective].

Lalive PH.

Rev Med Suisse. 2016 Mar 2;12(508):472-3. French. No abstract available.

PMID:
27089606
26.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board.

PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016.

27.

Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen.

Kinzel S, Lehmann-Horn K, Torke S, Häusler D, Winkler A, Stadelmann C, Payne N, Feldmann L, Saiz A, Reindl M, Lalive PH, Bernard CC, Brück W, Weber MS.

Acta Neuropathol. 2016 Jul;132(1):43-58. doi: 10.1007/s00401-016-1559-8. Epub 2016 Mar 29.

28.

Meningoencephalitis with microinfarcts in early neuroborreliosis.

Huys AC, Lalive PH, Haller S.

Neuroradiology. 2016 May;58(5):533-4. doi: 10.1007/s00234-016-1657-2. Epub 2016 Feb 9. No abstract available.

PMID:
26861491
29.

Gait variability in multiple sclerosis: a better falls predictor than EDSS in patients with low disability.

Allali G, Laidet M, Herrmann FR, Armand S, Elsworth-Edelsten C, Assal F, Lalive PH.

J Neural Transm (Vienna). 2016 Apr;123(4):447-50. doi: 10.1007/s00702-016-1511-z. Epub 2016 Feb 4.

PMID:
26846418
30.

Glatiramer acetate treatment negatively regulates type I interferon signaling.

Molnarfi N, Prod'homme T, Schulze-Topphoff U, Spencer CM, Weber MS, Patarroyo JC, Lalive PH, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 9;2(6):e179. doi: 10.1212/NXI.0000000000000179. eCollection 2015 Dec. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2015 Dec;2(6):e189.

31.

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.

Zimmermann M, Sanderson NS, Rasenack M, Lalive PH, Lang AB, Curtin F, Lindberg RL, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e144. doi: 10.1212/NXI.0000000000000144. eCollection 2015 Oct.

32.

[Clinical pharmacology of medical cannabinoids in chronic pain].

Ing Lorenzini K, Broers B, Lalive PH, Dayer P, Desmeules J, Piguet V.

Rev Med Suisse. 2015 Jun 24;11(480):1390, 1392-4. Review. French.

PMID:
26267945
33.

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

J Neuroimmunol. 2015 Aug 15;285:68-70. doi: 10.1016/j.jneuroim.2015.05.019. Epub 2015 May 20.

PMID:
26198921
34.

Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis.

Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH.

J Neuroimmunol. 2015 Aug 15;285:1-3. doi: 10.1016/j.jneuroim.2015.05.020. Epub 2015 May 21.

PMID:
26198911
35.

Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study.

Bridel C, Beauverd Y, Samii K, Lalive PH.

Neurol Neuroimmunol Neuroinflamm. 2015 Jun 18;2(4):e123. doi: 10.1212/NXI.0000000000000123. eCollection 2015 Aug.

36.

Successful long-term ambulatory norepinephrine infusions in a patient with pure autonomic failure.

Zekeridou A, Michel P, Medlin F, Hayoz D, Lalive PH, Kuntzer T.

Clin Auton Res. 2015 Aug;25(4):251-3. doi: 10.1007/s10286-015-0290-1. Epub 2015 Jul 3.

PMID:
26138858
37.

Hepatocyte growth factor: A regulator of inflammation and autoimmunity.

Molnarfi N, Benkhoucha M, Funakoshi H, Nakamura T, Lalive PH.

Autoimmun Rev. 2015 Apr;14(4):293-303. doi: 10.1016/j.autrev.2014.11.013. Epub 2014 Dec 1. Review.

PMID:
25476732
38.

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

Mult Scler. 2015 Jun;21(7):885-93. doi: 10.1177/1352458514554052. Epub 2014 Nov 12.

PMID:
25392325
39.

Update on multiple sclerosis treatments.

Bridel C, Lalive PH.

Swiss Med Wkly. 2014 Sep 23;144:w14012. doi: 10.4414/smw.2014.14012. eCollection 2014. Review.

40.

Transient gadolinium leakage in natalizumab-treated multiple sclerosis.

Haller S, Barkhof F, Wattjes MP, Lalive PH.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):475-6. doi: 10.1136/jnnp-2014-309069. Epub 2014 Sep 22. No abstract available.

PMID:
25246642
41.

Hepatocyte growth factor limits autoimmune neuroinflammation via glucocorticoid-induced leucine zipper expression in dendritic cells.

Benkhoucha M, Molnarfi N, Dunand-Sauthier I, Merkler D, Schneiter G, Bruscoli S, Riccardi C, Tabata Y, Funakoshi H, Nakamura T, Reith W, Santiago-Raber ML, Lalive PH.

J Immunol. 2014 Sep 15;193(6):2743-52. doi: 10.4049/jimmunol.1302338. Epub 2014 Aug 11.

42.

Minimal supportive treatment in natalizumab-related PML in a MS patient.

Lalive PH, Bridel C, Ferfoglia RI, Kaiser L, Du Pasquier R, Barkhof F, Haller S.

J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):354-5. doi: 10.1136/jnnp-2014-308154. Epub 2014 Jun 23. No abstract available.

PMID:
24957322
43.

Multifocal motor neuropathy with high titers of anti-MAG antibodies.

Bridel C, Horvath J, Kurian M, Truffert A, Steck A, Lalive PH.

J Peripher Nerv Syst. 2014 Jun;19(2):180-2. doi: 10.1111/jns5.12069.

PMID:
24863375
44.

Dual-task assessment in natalizumab-treated multiple sclerosis patients.

Allali G, Laidet M, Assal F, Chofflon M, Armand S, Lalive PH.

Eur Neurol. 2014;71(5-6):247-51. doi: 10.1159/000357217. Epub 2014 Feb 1.

PMID:
24503719
45.

Walking while talking in patients with multiple sclerosis: the impact of specific cognitive loads.

Allali G, Laidet M, Assal F, Armand S, Lalive PH.

Neurophysiol Clin. 2014 Jan;44(1):87-93. doi: 10.1016/j.neucli.2013.10.136. Epub 2013 Nov 6.

PMID:
24502909
46.

Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.

Salvisberg C, Tajouri N, Hainard A, Burkhard PR, Lalive PH, Turck N.

Proteomics Clin Appl. 2014 Apr;8(3-4):185-94. doi: 10.1002/prca.201300053. Epub 2014 Mar 7.

PMID:
24488530
47.

The neurotrophic hepatocyte growth factor induces protolerogenic human dendritic cells.

Molnarfi N, Benkhoucha M, Juillard C, Bjarnadóttir K, Lalive PH.

J Neuroimmunol. 2014 Feb 15;267(1-2):105-10. doi: 10.1016/j.jneuroim.2013.12.004. Epub 2013 Dec 11.

PMID:
24367900
48.

The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity.

Benkhoucha M, Molnarfi N, Schneiter G, Walker PR, Lalive PH.

J Neuroinflammation. 2013 Dec 17;10:154. doi: 10.1186/1742-2094-10-154.

49.

TLR7 signaling exacerbates CNS autoimmunity through downregulation of Foxp3+ Treg cells.

Lalive PH, Benkhoucha M, Tran NL, Kreutzfeldt M, Merkler D, Santiago-Raber ML.

Eur J Immunol. 2014 Jan;44(1):46-57. doi: 10.1002/eji.201242985. Epub 2013 Oct 1.

50.

Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.

Wullschleger A, Kapina V, Molnarfi N, Courvoisier DS, Seebach JD, Santiago-Raber ML, Hochstrasser DF, Lalive PH.

PLoS One. 2013 Aug 27;8(8):e72399. doi: 10.1371/journal.pone.0072399. eCollection 2013.

Supplemental Content

Loading ...
Support Center